Clinical Edge Journal Scan

Pre-pregnancy migraine: A potential risk factor for hypertensive disorders of pregnancy


 

Key clinical point: The risk for hypertensive disorders of pregnancy (HDOP) was significantly higher in women who experienced migraine before 20 weeks of pregnancy, with the risk being most prominent among women with migraine during the first trimester and those who used migraine medications.

Major finding: The risk for HDOP was significantly higher in women with vs without pre-pregnancy migraine (adjusted risk ratio [aRR] 1.17; 95% CI 1.09-1.26), with the risk being the highest in those with migraine that persisted during the first trimester (aRR 1.84; 95% CI 1.35-2.50) and in those who received migraine-specific medication (aRR 1.50; 95% CI 1.15-1.97).

Study details: Findings are from a population-based prospective cohort study including 1,049,839 women without a history of cardiovascular diseases or hypertension who had liveborn or stillborn singleton deliveries, of which 127,295 women had pre-pregnancy migraine.

Disclosures: This study was supported by the National Institute of Child Health and Human Development, US National Institutes of Health. The authors declared no conflicts of interest.

Source: Crowe HM et al. Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study. Cephalalgia. 2023;43(4):3331024231161746 (Mar 19). Doi: 10.1177/03331024231161746

Recommended Reading

Galcanezumab improves interictal burden in patients with migraine with multiple treatment failures
Migraine ICYMI
Real-world study: Predictors of poor response to galcanezumab in chronic migraine
Migraine ICYMI
Benign paroxysmal positional vertigo associated with higher risk for migraine
Migraine ICYMI
Traumatic brain injury raises risk for subsequent migraine
Migraine ICYMI
Migraine: Identifying clinical traits of super-responders vs non-responders to CGRP-R mAb
Migraine ICYMI
Fremanezumab shows favorable benefit-risk profile in difficult-to-treat migraine
Migraine ICYMI
Real-world study compares benefits for patients with migraine of mAb against CGRP and its receptor
Migraine ICYMI
Meta-analysis compares efficacy of lasmiditan, rimegepant, and ubrogepant for acute treatment of migraine
Migraine ICYMI
Looking at CGRP-Related Medications for Migraine, April 2023
Migraine ICYMI
Galcanezumab shows wearing-off effects but only in patients with chronic migraine
Migraine ICYMI